Literature DB >> 21175580

Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.

Masatsugu Horiuchi1, Masaki Mogi.   

Abstract

Recent clinical studies have demonstrated that angiotensin II type 1 (AT(1) ) receptor blockers (ARBs) reduce the onset of stroke, stroke severity and the incidence and progression of Alzheimer's disease and dementia. We can expect that ARBs exert these effects by both AT(1) receptor blockade and angiotensin II type 2 (AT(2) ) receptor stimulation. Moreover, recent experimental results support the notion that AT(2) receptor stimulation with AT(1) receptor blockade could contribute to protection against ischaemic brain damage at least partly due to an increase in cerebral blood flow and decrease in oxidative stress, and prevent cognitive decline. Cellular therapy has been focused on as a new therapeutic approach to restore injured neurons. In this context, it has been reported that AT(2) receptor stimulation enhances neurite outgrowth and decreases neural damage, thereby enhancing neurogenesis. Moreover, additional beneficial effects of ARBs with an AT(1) receptor blocking action with a partial peroxisome proliferator-activated receptor (PPAR)-γ agonistic effect have been reported, and interaction of AT(2) receptor activation and PPAR-γ might be involved in these ARBs' effects. This article reviews the effects of regulation of activation of angiotensin II receptor subtypes on ischaemic brain damage and cognitive function, focusing on the effects of AT(2) receptor stimulation.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175580      PMCID: PMC3144529          DOI: 10.1111/j.1476-5381.2010.01167.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  82 in total

Review 1.  Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT( 1 ) Receptor Antagonists in the Brain.

Authors:  Juan M Saavedra; Julius Benicky; Jin Zhou
Journal:  Cell Mol Neurobiol       Date:  2006-04-25       Impact factor: 5.046

2.  Ischemic injury in experimental stroke depends on angiotensin II.

Authors:  Thomas Walther; Laszlo Olah; Christoph Harms; Bjoern Maul; Michael Bader; Heide Hörtnagl; Heinz-Peter Schultheiss; Günter Mies
Journal:  FASEB J       Date:  2002-02       Impact factor: 5.191

3.  Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.

Authors:  Meiko Hamai; Masaru Iwai; Ayumi Ide; Hirokazu Tomochika; Yumiko Tomono; Masaki Mogi; Masatsugu Horiuchi
Journal:  Neuropharmacology       Date:  2006-07-07       Impact factor: 5.250

4.  Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.

Authors:  Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Kana Tsukuda; Masaru Iwai; Masatsugu Horiuchi
Journal:  Hypertension       Date:  2006-06-12       Impact factor: 10.190

5.  Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke.

Authors:  Li Hong Shen; Yi Li; Jieli Chen; Alex Zacharek; Qi Gao; Allissa Kapke; Mei Lu; Kim Raginski; Padmayathy Vanguri; Alan Smith; Michael Chopp
Journal:  J Cereb Blood Flow Metab       Date:  2006-04-05       Impact factor: 6.200

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells.

Authors:  Nanping Wang; Lynne Verna; Neng-Guin Chen; Jasmine Chen; Hongling Li; Barry Marc Forman; Michael B Stemerman
Journal:  J Biol Chem       Date:  2002-07-09       Impact factor: 5.157

8.  AGTR2 mutations in X-linked mental retardation.

Authors:  Virginie S Vervoort; Michael A Beachem; Penny S Edwards; Sydney Ladd; Karin E Miller; Xavier de Mollerat; Katie Clarkson; Barbara DuPont; Charles E Schwartz; Roger E Stevenson; Ellen Boyd; Anand K Srivastava
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

9.  Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

Authors:  Doris M Tham; Baby Martin-McNulty; Yi-xin Wang; Dennis W Wilson; Ronald Vergona; Mark E Sullivan; William Dole; John C Rutledge
Journal:  Physiol Genomics       Date:  2002-10-02       Impact factor: 3.107

10.  Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist.

Authors:  Takeshi Ito; Haruki Yamakawa; Claudia Bregonzio; José A Terrón; Alicia Falcón-Neri; Juan M Saavedra
Journal:  Stroke       Date:  2002-09       Impact factor: 7.914

View more
  20 in total

Review 1.  Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress.

Authors:  Hyun Ah Kim; Alyson A Miller; Grant R Drummond; Amanda G Thrift; Thiruma V Arumugam; Thanh G Phan; Velandai K Srikanth; Christopher G Sobey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-08       Impact factor: 3.000

2.  Mechanical activation of angiotensin II type 1 receptors causes actin remodelling and myogenic responsiveness in skeletal muscle arterioles.

Authors:  Kwangseok Hong; Guiling Zhao; Zhongkui Hong; Zhe Sun; Yan Yang; Philip S Clifford; Michael J Davis; Gerald A Meininger; Michael A Hill
Journal:  J Physiol       Date:  2016-10-13       Impact factor: 5.182

Review 3.  The role of sphingolipids in endothelial barrier function.

Authors:  Peter L Jernigan; Amy T Makley; Richard S Hoehn; Michael J Edwards; Timothy A Pritts
Journal:  Biol Chem       Date:  2015-06       Impact factor: 3.915

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Telmisartan Protects Against Aluminum-Induced Alzheimer-like Pathological Changes in Rats.

Authors:  Mona Khalifa; Marwa M Safar; Rania M Abdelsalam; Hala F Zaki
Journal:  Neurotox Res       Date:  2019-07-22       Impact factor: 3.911

Review 6.  Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

7.  Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation.

Authors:  Eun-Ji Koh; Seong-Jin Yoon; Sun-Mee Lee
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

Review 8.  The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene.

Authors:  Tamara Kobiec; Matilde Otero-Losada; Guenson Chevalier; Lucas Udovin; Sofía Bordet; Camila Menéndez-Maissonave; Francisco Capani; Santiago Pérez-Lloret
Journal:  Front Synaptic Neurosci       Date:  2021-04-22

9.  ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke.

Authors:  Teng Jiang; Li Gao; Jie Lu; Ying-Dong Zhang
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

10.  How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations?

Authors:  Marie-Odile Guimond; Nicole Gallo-Payet
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-19       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.